Sistema complementario

Anti-GC1q R/C1QBP Antibody (60.11) is a mouse IgG1, κ chimeric antibody designed to target human GC1q R/C1QBP. The recommended isotype control for this antibody is Mouse IgG1 kappa, Isotype Control.

FD-IN-1 is an orally active Factor D (FD) inhibitor (IC50=12 nM), inhibits Factor XIa and Tryptase β2 with IC50 values of 7.7 and 6.5 μM, respectively.

ASP-1948 is a human monoclonal antibody targeting NRP1/VEGF165R/CD34. It is capable of reversing the inhibitory effects of regulatory T cells and can be applied in the study of solid tumors.

Anti-CD88/C5AR1 Antibody (G2_anti-C5aR) is a human monoclonal antibody (mAb) targeting C5AR1.

MEDI7814 is a humanized monoclonal antibody inhibitor targeting C5a and C5adesArg. It has binding affinities of 14 pM for recombinant human C5a and 8 pM for serum-purified human C5a. MEDI7814 shows potential for treating acute inflammatory conditions, including sepsis and renal ischemia-reperfusion injury.

Complement C5-IN-1 is a small-molecule inhibitor of complement component 5 protein (C5).

EG00229 blocks VEGF-A/NRP1 binding, IC50 of 3 μM; doesn't affect VEGFR-1/2. It's an NRP1 antagonist.

NDT 9513727 is a potent, selective and competitive C5aR1 inverse agonist for the study of inflammatory and immune disorders.

C3a Receptor Agonist activates C3aRs, inhibits neutrophil mobilization in ischemia, and promotes neural progenitor differentiation.

Factor B-IN-2 is a potent inhibitor (IC50: 1.5 μM) of complement factor B. Factor B-IN-2 can be used to study inflammatory and immune-related diseases.

EG01377 is a NRP1 antagonist with antiangiogenic, antimigratory, and antitumor activity, Kd 1.32 μM, IC50s 609 nM for NRP1-a1/b1, inactive on NRP2.

W-54011: potent non-peptide C5a receptor blocker; binds 125I-C5a (Ki=2.2nM); stops Ca2+ movement, chemotaxis, ROS in neutrophils (IC50=1.6-3.1nM).

Vemircopan is a complement factor D inhibitor.

Factor D inhibitor 6 is a potent, highly selective, and orally active compound that specifically inhibits the activity of factor D (FD) with an IC₅₀ of 30 nM and a Kd of 6 nM. It does not exhibit inhibitory effects against factor B, classical and lectin complement-pathway activation, or a broad array of receptors, ion channels, kinases, and proteases.

C5aR-IN-1, a potent C5aR inhibitor, may aid in researching autoimmune and inflammatory diseases.

Iptacopan (LNP023) is an inhibitor with high affinity to factor B, with a KD value of 7.9 nM and an IC50 value of 10 nM. Cost-effective and quality-assured.

4-Octylphenol is an endocrine disruptor with gender-specific effects on male germ cells, significantly reducing the mitotic index and the number of spermatogonia. It also causes inflammatory damage in the gills of carp by activating the complement system through the C3a/C3a receptor (C3a/C3aR) axis and C5a/C5a receptor 1 (C5a/C5aR1) axis. Furthermore, 4-Octylphenol induces immune suppression by disrupting the balance between helper T (Th) cells 1/Th2 and regulatory T (Treg)/Th17 cells, and triggers inflammatory damage through the Toll-like receptor 7 (Toll-like Receptor (TLR))/inhibitor κBα/nuclear factor κB (TLR7/IκBα/NF-κB) pathway.

Factor B-IN-6 is an orally bioavailable inhibitor of Factor B. It exhibits significant inhibitory activity on the activation of the human serum alternative pathway. In model animals, Factor B-IN-6 can improve kidney lesions and function, reducing urinary protein levels. Factor B-IN-6 is applicable for kidney disease research.

Refinicopan is a complement factor D inhibitor with an IC50 of 10 nM, demonstrating an inhibition activity on rabbit erythrocyte hemolysis with an IC50 of 41 nM. It possesses excellent pharmacokinetic and pharmacodynamic properties.

Bisphenol S disulfate disodium acts as a complement inhibitor (IC50 = 660 μM).